We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Sheffield NHS Lab Moves to Advanced Micorarrays Platform

By LabMedica International staff writers
Posted on 08 Feb 2015
Print article
A case study discusses Sheffield laboratory’s experience of switching to a more efficient and reliable microarrays platform for cytogenetic research.

Advances in array design and analysis capabilities mean that choosing a platform can be challenging. A new case study by Oxford Gene Technology (OGT; Oxfordshire, UK) explores how Sheffield Children's NHS Foundation Trust (UK) has seamlessly transferred to its CytoSure ISCA 8x60k platform. Upon a highly stringent National Health Service (NHS, UK) tender for the supply of oligo-based cytogenetics research arrays, CytoSure was selected based on the quality of data and analysis software. It was the only platform able to correctly identify all the genetic abnormalities tested.

The NHS carried out a comprehensive comparison of multiple array platforms in order to select the most effective solution (considering quality of results, ease of use and cost) via a consortium led by four prominent laboratories. Chosen over alternatives, the success of the CytoSure ISCA array, designed in partnership with the International Collaboration for Clinical Genomics (ICCG), was attributed to a combination of the array and CytoSure Interpret Software performance. Every lab submitted a set of challenging samples to be processed by OGT, and the results came back clean and clear, with the data interpretation software greatly facilitating analysis.

Maintaining productivity within the laboratory, OGT worked hard to ensure a seamless transfer process. In addition to getting the new system itself up and running, the team also provided on-site operational training, software tutorials, and transfer of local legacy data to the CytoSure Interpret Software database. “I can only be extremely positive about the whole process of switching to OGT’s CytoSure platform, so if anyone asks me if it’s worth the time and effort of transferring, the answer is a clear yes,” said Kath Smith, consultant clinical scientist at Sheffield’s. James Clough, Executive Vice President Commercial at OGT, commented, “It’s a pleasure to welcome Sheffield Children's NHS Foundation Trust to OGT. Customer satisfaction is extremely important to us, so it’s great to get such positive feedback on our products and support. It’s a testament to our team’s hard work and dedication.”

A 3 month data audit has revealed more accurate aneuploidy calling, leading to fewer uncertain cases and saving time and resources involved in follow-up investigations. The switch has also benefited Sheffield’s lab from the practicality of high-throughput plate-based labeling through to enhancing its overall operation in a more cost-effective manner.

CytoSure is provided under an agreement between Agilent Technologies and OGT. The product is for research use only and not for diagnostic or other medical use.

Related Links:

Oxford Gene Technology
Evaluating and switching to CytoSure microarrays, OGT case study 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.